Qasim Parekh

Results-driven pharmaceutical business professional with a proven track record in the pharmaceutical industry. Skilled in developing and executing customized sales strategies to maximize brand recognition and drive revenue growth. Exceptional at building and maintaining strong relationships with key healthcare professionals.

Demonstrates a deep understanding of patient-centric needs, delivering optimal solutions to improve patient outcomes. A persuasive communicator who simplifies complex scientific information, asks probing questions, and recommends tailored product solutions. Fluent in English, Urdu, Hindi, and Punjabi.

Spec Rep (Women's Health) at Knight Therapeutics (2024-01 – 2026-01)

• Performed a SWOT Analysis of territory covering Hamilton, Niagara, Burlington, Oakville and Mississauga to quickly define and seize on opportunities to penetrate the market and advance business growth.
• Emphasized product strengths to validate the unique value proposition of Imvexxy and Bijuva combined with Physician sample testing to increase Imvexxy from zero revenue in the first three months of launch to 60% MOM growth.
• Developed and executed strategic territory plan by zoning territory for optimum routing and placing greater emphasis on high decile customers. Gained knowledge on key influencers within OB/GYN specialty and identified opportunities to plan Med-Ed programs.
• Planned and executed multiple lunch and learns and OLAs within first three months of hiring.
• Researched and evaluated the market uncovering untapped opportunities by reaching out to pharmacies, to uncover new customers and educate pharmacists on the safety, efficacy and benefits of estradiol and hormone replacement therapy.
• Collaborated with cross-functional teams (MSLs, Marketing) to support customer's unmet needs and incorporate speaker development.
• Utilized an omni-channel approach to reach out to customers who were in remote locations via emails and virtual lunch and learn. Collaborated with team members to invite key customers for optimized distribution of brand messaging and customer engagement.
• Communicated key customer insights to team members and senior management to leverage more engaged calls with customers and gain commitment by offering solutions to the problem that matters the most.
• Developed a business plan based on the brand strategy, proactively communicated with senior management for feedback, and implemented the feedback for optimum territory activity.
• Performed administrative tasks in a timely fashion.

GSK - Respirology Sales Representative at IMPRES PHARMA (2022-01 – 2023-08)

• Positioned Trelegy brand as the best choice for uncontrolled asthma patient by leveraging evidence based medicine and ease of use.
• Developed strong Family Physician relationship by learning and understanding their patient needs by asking the right probing question.
• Developed strong partnerships by identifying key pain points of the patient and leveraged Trelegy value proposition of its efficacy, safety and ease of use to achieve best asthma control.
• Organized tailored Continuing Medical Education (CME) programs, with an average attendance rate of 80%, increasing awareness and driving a 30% growth in new prescription volume for Trelegy.
• Successfully identified and addressed local prescribing barriers for priority accounts, utilizing thorough market research and understanding healthcare providers' unique challenges to tailor effective solutions.
• Implemented educational programs to increase product awareness, collaborated with healthcare institutions to streamline access processes, and conducted training sessions to address concerns and misconceptions.
• Conducted a SWOT analysis of the territory, identified areas for improvement, and actively collaborated with cross-functional teams to drive business growth.
• Identified and targeted 20 high-potential customers with private prescribing potential, resulting in a 50% increase in revenue from those accounts.
• Achieved over 30% growth in market share in short period of employment, resulting in recognition from senior management and receipt of performance-based bonus.
• Achieved outstanding results at GSK by developing and implementing cross-functional key account business plans, aligning strategies with strategic brand objectives, and driving a 30% growth in market share in new prescription volume for Trelegy, positioning it as the preferred choice for uncontrolled asthma.
• Led comprehensive market analyses, identified key stakeholders, and formulated customer engagement strategies, resulting in optimized brand growth, market penetration, and increased brand visibility in the Key Account Manager role.
• Successfully addressed challenges related to uncontrolled asthma by collaborating with cross-functional teams, educating healthcare professionals on newer guidelines and improved therapeutics, and implementing strategies to redefine asthma control, leading to improved patient outcomes and increased market share.

Oral Health-Care Representative at Philips (2022-01 – 2022-12)

International health technology company focused on diagnosis, preventing disease and helping people live better.

• Developed strong partnerships and relationships with dentist, dental hygienist, dental assistant and patient co-ordinator to improve patient health outcome with Sonicare and Zoom Whitening brands.
• Identified key issues and presented viable solutions via proper training of zoom whitening, value add proposition of Sonicare & Zoom whitening to patients for better patient retention, treatment acceptance and new patient acquisition.
• Challenged with poor serviced territory due to turn over. Reached out to key customers to address challenges and developed tailored solutions, which included training, education and right way of marketing Philips Sonicare and zoom whitening portfolio.
• Turned territory from loosing revenue to 60% sales growth and meeting sales quota.

CNS Representative at LUNDBECK (2016-01 – 2021-12)

International research-based pharmaceutical company focused on brain diseases. Based in Montreal, Lundbeck Canada has been active in the Canadian pharmaceutical industry for over two decades, marketing products to treat brain diseases such as depression, anxiety, Alzheimer's disease, schizophrenia, and bipolar disorders.

• Charged with boosting the volume of prescribers for Trintellix® to minimize the reliance solely on Psychiatrists and target Family Physicians to be able to administer the drug for depression to expedite treatment before patients visit with Psychiatrist.
• Consistently exceeded sales targets of Trintellix, achieving over 35% year-over-year sales growth within the first 2 years.
• Implemented patient-centric approach, guiding physicians to focus on tailored treatment with techniques such as receptor profiling for specific patients.
• Developed influential key speakers, emphasizing methodology and rationale for product selection, resulting in increased physician engagement and acceptance of patient-centric solutions.
• Advocated for physicians to become proficient in treating depression via receptor-profiling, enabling optimal patient outcomes.
• Delivered average annual sales growth of 25% over a 7-year period, consistently surpassing sales quotas.
• Positioned Trintellix as top market leader in private market and maintained that position.
• Gained an understanding of rationale of the clinical algorithm used by Physicians when selecting an anti-depressant as Trintellix®, which became a niche product for switch patients and reserved for treating difficult to treat patients leading to slow sales.
• Focused on ways to empower patients to develop trust, discussing most up to date and current studies. Championed the concept of patient fit to treatment to match their expectation and aim for recommending Trintellix® to the best responders.
• Partnered with KOLs to untangle and clarify through Physician education anxiety pathways using anatomy and psychopharmacology to distinguish between General Anxiety (GAD) which was not indicated for Trintellix® and co-morbid anxiety indicated for Trintellix® to boost business in ethical approach.
• Advocated by partnering with KOL's for the adoption of receptor profiling in treating depression, improving treatment success rate from 30% to 70% and over 50% increase in patient remission rates.
• Challenged to increase sales and position the newly released Rexulti® an atypical anti-psychotic with superior efficacy and tolerability as easy to use and safe adjunctive treatment for major depressive disorder.

(HONS) B.SC